论文部分内容阅读
目的分析青年女性乳腺癌的临床治疗效果和病理特征。方法 410例乳腺癌患者,50例青年女性乳腺癌患者(年龄≤35岁)作为实验组;360例中老年女性乳腺癌患者(>35岁)作为对照组,对两组患者的临床病理资料、免疫组化指标[雌激素受体(ER)、孕激素受体(PR)、癌基因HER-2、P53]进行观察比较。结果实验组淋巴结转移率(38.0%)以及组织学分级(Ⅱ/Ⅲ级)(92.0%)显著高于对照组(25.8%、80.0%)(P<0.05),而两组病理类型以及肿瘤直径比较差异无统计学意义(P>0.05)。实验组ER、PR、HER-2以及P53的阳性例数分别为28例、30例、25例、27例,对照组分别为245例、252例、144例、201例,实验组PR、ER表达阳性率显著低于对照组,HER-2表达阳性率显著高于对照组(P<0.05)。结论在临床病理特征方面,青年女性乳腺癌具有自身的特殊性,临床中在对青年女性乳腺癌患者进行治疗时,应及早诊断,并给予科学和合理的治疗方法 ,进而来提高临床治疗效果,改善患者预后。
Objective To analyze the clinical effect and pathological features of young female breast cancer. Methods A total of 410 cases of breast cancer patients and 50 cases of young female breast cancer patients (≤35 years old) were selected as the experimental group. 360 cases of middle-aged and elderly female breast cancer patients (> 35 years old) served as control group. The clinical pathological data, Immunohistochemical indicators [estrogen receptor (ER), progesterone receptor (PR), oncogene HER-2, P53] were observed and compared. Results The lymph node metastasis rate (38.0%) and histological grade (92.0%) in the experimental group were significantly higher than those in the control group (25.8%, 80.0%) (P <0.05) The difference was not statistically significant (P> 0.05). The positive cases of ER, PR, HER-2 and P53 in experimental group were 28 cases, 30 cases, 25 cases and 27 cases respectively. The control group were 245 cases, 252 cases, 144 cases and 201 cases. The positive expression rate of HER-2 was significantly lower than that of the control group (P <0.05). Conclusion In terms of clinical and pathological features, young women with breast cancer have their own particularity. In the clinical treatment of young women with breast cancer, they should be diagnosed as soon as possible and given a scientific and rational treatment to improve the clinical treatment effect, Improve patient’s prognosis.